التفاصيل البيبلوغرافية
| العنوان: |
Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. |
| المؤلفون: |
Burkard, Mark E., Deming, Dustin A., Parsons, Benjamin M., Kenny, Paraic A., Schuh, Marissa R., Leal, Ticiana, Uboha, Nataliya, Lang, Joshua M., Thompson, Michael A., Warren, Ruth, Bauman, Jordan, Mably, Mary S., Laffin, Jennifer, Paschal, Catherine R., Lager, Angela M., Lee, Kristy, Matkowskyj, Kristina A., Buehler, Darya G., Rehrauer, William M., Kolesar, Jill |
| المصدر: |
JCO Precision Oncology; 2017, Vol. 1 Issue 1, p1-10, 10p |
| مصطلحات موضوعية: |
INDIVIDUALIZED medicine, TUMORS, CLINICAL trials, CANCER treatment, MOLECULAR models |
| مستخلص: |
Purpose: Precision oncology develops and implements evidence-based personalized therapies that are based on specific genetic targets within each tumor. However, a major challenge that remains is the provision of a standardized, up-to-date, and evidenced-based precision medicine initiative across a geographic region. Materials and Methods: We developed a statewide molecular tumor board that integrates academic and community oncology practices. The Precision Medicine Molecular Tumor Board (PMMTB) has three components: a biweekly Web-based teleconference tumor board meeting provided as a free clinical service, an observational research registry, and a monthly journal club to establish and revise evidence-based guidelines for off-label therapies. The PMMTB allows for flexible and rapid implementation of treatment, uniformity in practice, and the ability to track outcomes. Results: We describe the implementation of the PMMTB and its first year of activity. Seventy-seven patient cases were presented, 48 were enrolled in a registry, and 38 had recommendations and clinical follow-up. The 38 subjects had diverse solid tumors (lung, 45%; GI, 21%; breast, 13%; other, 21%). Of these subjects, targeted therapy was recommended for 32 (84%). Clinical trials were identified for 24 subjects (63%), and nontrial targeted medicines for 16 (42%). Nine subjects (28%) received recommended therapy with a response rate of 17% (one of six) and a clinical benefit rate (partial response + stable disease) of 38% (three of eight). Although clinical trials often were identified, patients rarely enrolled. Conclusion: The PMMTB provides a model for a regional molecular tumor board with clinical utility. This work highlights the need for outcome registries and improved access to clinical trials to pragmatically implement precision oncology. [ABSTRACT FROM AUTHOR] |
|
Copyright of JCO Precision Oncology is the property of American Society of Clinical Oncology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
